Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046072 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00046072 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 300 participants.
The verdict
NCT00046072, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death. Much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. An endotoxin antagonist is designed to block the effects of endotoxin. This study is designed to study the safety and efficacy when treating patients with severe sepsis.
Interventions
- DRUG E5564
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2001-10 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046072
The ClinicalTrials.gov registry entry for NCT00046072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E5564 is the first listed.
NCT00046072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046072 about?
NCT00046072 is a clinical study titled "A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis". Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death. Much of the injury is due to endotoxin, a harmful...
What is the current status of trial NCT00046072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2001-10. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00046072?
The interventions under investigation include: E5564 (DRUG).
Who is sponsoring clinical trial NCT00046072?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.